We are investigating aberrant glutamine metabolism in breast cancer to discover potential novel therapeutic targets to inhibit a critical energy source for cancer cells. We have examined glutamine and glutamate levels using 1H magnetic resonance spectroscopy (MRS) across multiple breast cancer cell types and have begun to look at the molecular mechanisms of glutamine addiction using qRT-PCR. We identified SLC38A3 to be overexpressed in nearly every breast cancer cell line examined, which may, in the future, serve as a potential target in breast cancer.
This abstract and the presentation materials are available to members only; a login is required.